Aspen Neuroscience, Inc.

What the company does

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell-derived therapies for neurodegenerative diseases. Its lead product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy being evaluated for Parkinson’s disease. The company is also developing a microglia program targeting pediatric leukodystrophies and operates an integrated end-to-end autologous iPSC platform.

Use of proceeds

The company intends to use the net proceeds from the offering, together with existing cash, cash equivalents and marketable securities, to fund clinical development of sasineprocel, including the ongoing Phase 1/2a ASPIRO trial and initiation of a Phase 3 trial in sporadic and genetic Parkinson’s disease. The proceeds will also fund research and development of other product candidates and be used for working capital and general corporate purposes.

Underwriters

Extracted from 424B4 0001193125-26-441782, filed Oct 30, 2026 and verified against that filing text.

Key risk factors

• Limited operating history

  “We are a clinical-stage regenerative medicine biotechnology company with a limited operating history and no history of commercializing products, which may make it difficult to evaluate our approach to the discovery and development of product candidates and the prospects for our future viability.”

• Substantial operating losses

  “We have incurred substantial operating losses since our inception and expect to incur substantial losses for the foreseeable future.”

• Going concern uncertainty

  “Our financial condition raises substantial doubt as to our ability to continue as a going concern.”

• Additional capital requirements

  “Even if this offering is successful, we will require substantial additional capital to finance our operations, and failure to obtain additional capital when needed, or on acceptable terms, could cause us to delay, limit, reduce, or terminate product development programs, commercialization efforts or other operations.”

• Dependence on sasineprocel

  “We currently depend on the success of sasineprocel, which is our lead product candidate.”

• Novel treatment approach

  “Sasineprocel is based on a novel approach to treat PD, which makes it difficult to predict the time and cost of product candidate development and to obtain regulatory approval, if at all.”

• Uncertain clinical development

  “Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.”

• Regulatory approval uncertainty

  “The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.”